# OnCo record gist (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/gist/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "gist" ;
  schema:name "Gastrointestinal stromal tumour (GIST)"@en ;
  schema:description "GIST is a sarcoma of the gut wall driven almost always by a KIT or PDGFRA mutation. It was the proof that a pill can control a solid tumour: imatinib turned a median survival of about a year into one of eight years or more, and the mutation now dictates which drug to use."@en ;
  schema:url <https://onco.cc/cancers/gist/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Gastrointestinal_stromal_tumor> ;
  owl:sameAs <http://www.wikidata.org/entity/Q1495661> ;
  schema:citation <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1507>, <https://doi.org/10.1016/j.annonc.2021.09.005>, <https://liferaftgroup.org/> ;
  onco:tag "gap-fill", "gastrointestinal", "sarcoma" ;
  onco:related <https://onco.cc/cancers/leiomyosarcoma/>, <https://onco.cc/cancers/desmoid-tumour/>, <https://onco.cc/cancers/inflammatory-myofibroblastic-tumour/>, <https://onco.cc/cancers/dermatofibrosarcoma-protuberans/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/liquid-biopsy/>, <https://onco.cc/technologies/robotic-surgery/>, <https://onco.cc/technologies/endoscopic-resection/> ;
  onco:targets <https://onco.cc/targets/kit/>, <https://onco.cc/targets/pdgfra/>, <https://onco.cc/targets/ntrk/>, <https://onco.cc/targets/braf/> ;
  onco:drugs <https://onco.cc/drugs/imatinib/>, <https://onco.cc/drugs/sunitinib/>, <https://onco.cc/drugs/regorafenib/>, <https://onco.cc/drugs/ripretinib/>, <https://onco.cc/drugs/avapritinib/>, <https://onco.cc/drugs/temozolomide/> ;
  onco:companies <https://onco.cc/companies/novartis/>, <https://onco.cc/companies/pfizer/>, <https://onco.cc/companies/bayer/>, <https://onco.cc/companies/deciphera/>, <https://onco.cc/companies/sanofi/> ;
  onco:pathways <https://onco.cc/pathways/ras-mapk/>, <https://onco.cc/pathways/pi3k-akt-mtor/> ;
  onco:terms <https://onco.cc/terms/oncogene-addiction/>, <https://onco.cc/terms/resistance/>, <https://onco.cc/terms/ctdna/>, <https://onco.cc/terms/gist-risk-stratification/>, <https://onco.cc/terms/sdh-deficiency/> ;
  onco:trials <https://onco.cc/trials/nct07585266/>, <https://onco.cc/trials/nct05208047/>, <https://onco.cc/trials/nct07218926/>, <https://onco.cc/trials/nct07379047/>, <https://onco.cc/trials/nct03673501/>, <https://onco.cc/trials/grid/>, <https://onco.cc/trials/navigator/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-casali-ann-oncol/> ;
  onco:pipeline <https://onco.cc/drugs/ripretinib/>, <https://onco.cc/drugs/avapritinib/>, <https://onco.cc/technologies/liquid-biopsy/>, <https://onco.cc/drugs/velzatinib/>, <https://onco.cc/drugs/bezuclastinib/>, <https://onco.cc/drugs/idrx-42/>, <https://onco.cc/drugs/nb003/> ;
  onco:standardOfCare <https://onco.cc/drugs/imatinib/>, <https://onco.cc/drugs/imatinib/>, <https://onco.cc/drugs/avapritinib/>, <https://onco.cc/drugs/sunitinib/>, <https://onco.cc/drugs/ripretinib/>, <https://onco.cc/technologies/liquid-biopsy/>, <https://onco.cc/drugs/regorafenib/>, <https://onco.cc/drugs/ripretinib/> .